Ipilimumab augments antitumor activity of bispecific antibody-armed T cells

BACKGROUND: Ipilimumab is an antagonistic monoclonal antibody against cytotoxic T-lymphocyte antigen-4 (CTLA-4) that enhances antitumor immunity by inhibiting immunosuppressive activity of regulatory T cells (Treg). In this study, we investigated whether inhibiting Treg activity with ipilimumab duri...

Descripción completa

Detalles Bibliográficos
Autores principales: Yano, Hiroshi, Thakur, Archana, Tomaszewski, Elyse N, Choi, Minsig, Deol, Abhinav, Lum, Lawrence G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4105782/
https://www.ncbi.nlm.nih.gov/pubmed/25008236
http://dx.doi.org/10.1186/1479-5876-12-191

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4105782/
https://www.ncbi.nlm.nih.gov/pubmed/25008236
http://dx.doi.org/10.1186/1479-5876-12-191

Ejemplares similares